BarbaraJ.A.: Advances in transfusion safety. Experiences with genetic screening for established and new agents.Dev Biol Stand, 102: 99–103, 1999.
4.
BarbaraJ.A.: NAT: perspectives for cellular components.Biologicals, 27: 333–336, 1999.
5.
BarbaraJ.A.J.FlanaganP.: Blood transfusion risk: protecting against the unknown.BMJ, 316: 717–718, 1998.
6.
BarbaraJ.A.J.MullerJ.Y.: The side effects of blood transfusion, transmissible infections.In: Transfus medicine, a European course on blood transfusion, W Van Aken, B Genetet, 13: 273–311, 1994.
7.
BarbaraJ.A.J.: Does GB virus C (‘hepatitis G virus’) threaten the safety of the blood supply?Transfus Med, 7: 75–76, 1997.
8.
FlanaganP.SnapeT.: Nucleic acid technology (NAT) testing and the transfusion service: a rationale for the implementation of minipool testing.Transfus Med, 8: 9–13, 1998.
9.
MollisonP.L.EngelfrietC.P.ContrerasM.: Blood transfusion in clinical medicine. Infectious agents transmitted by transfusion.Blackwell Science, 16: 509–557, 1997.
10.
ReganF.A.M.HewittP.E.BarbaraJ.A.ContrerasM.: Prospective investigation of transfusion transmitted infection in recipients of over 20,000 units of blood.BMJ, 320: 403–406, 2000.
11.
SHOT: 3rd annual report of the serious hazards of transfusion steering group, 1998–1999.